Will Avacta deliver on the Rapid Antigen Test...64K question29 Oct 2020 00:10
Hello all,
Most stocks are down as people are unsure on the US election outcome and the impact on the global economy depending on who wins, as we all know.
However, right now for Avacta there is an elephant in the room and that is the rapid Antigen test delivery and / or timeline.
I am a previous investor in Avacta from the 67p days here. Potentially looking to get back into the stock. If we can get the rapid Antigen test delivered then I still believe this share would go North of Β£5. It has existing business aside from the rapid Antigen test with bigger potential in the long term. But many bought in for the medium term too.
My point that I made back in the summer was that timing of the rapid Antigen test was key, partly to get early mover advantage but also because the opportunity to monetise the rapid test solution and help fight Covid19 will only reduce as time goes by. As competitor products are hitting the market and the vaccine will hopefully be here soon. Even when the vaccine is here, there will still be a need for rapid testing for a period. My fear is whether Avacta will deliver the test now or how long it will take to deliver. As they have now missed the timelines given to the market which was summertime. I was hoping that would be during the summertime not at the end of it.
At the outset Alistair was particularly vague in his interviews to give timelines to deliver the test. I understand it was hard to predict. But others have by now so there seems to be issues around our test which hopefully will be sorted soon. He said sometime in the summer. Well summertime has now ended. Like it or not, Avacta has failed on that timeline and pretty miserably to be honest. I say that as I am frustrated that other companies seized the opportunity to get the product to market. The only updates we seem to get is employee share issues being handed out when the rapid test product has not even made it to market.
Aside from that negativity. At these levels of Β£160s...given you have the institutional backing at the Β£1.20s - this share still represents very good upside....if we can deliver the rapid Antigen test soon.
I am now at the conclusion that Avacta is definitely worth a punt but at investment levels where you can take a hit if they do not end up delivering the rapid Antigen test.
I hope the long-term holders get rewarded just like the NCYT holders were.
Gl all